Last reviewed · How we verify
Natural Treatment
Natural Treatment, marketed by Ann & Robert H Lurie Children's Hospital of Chicago, holds a unique position in the pediatric healthcare segment. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity. The primary risk lies in the lack of clear revenue data and key trial results, which may affect investor confidence and market adoption.
At a glance
| Generic name | Natural Treatment |
|---|---|
| Also known as | Yobee |
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
- WEB-BASED FILIAL THERAPY IN PEDIATRIC CANCER (NA)
- Host Response to Infection and Treatment in Filarial Diseases
- Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
- NCI COVID-19 in Cancer Patients, NCCAPS Study
- Characterization of Phenotypic and Genotypic Regressors for Imaging
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Natural Treatment CI brief — competitive landscape report
- Natural Treatment updates RSS · CI watch RSS
- Ann & Robert H Lurie Children's Hospital of Chicago portfolio CI